Raymond James Financial Services Advisors Inc. trimmed its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 3.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,545 shares of the medical technology company’s stock after selling 128 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Teleflex were worth $737,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Cornerstone Capital Management Holdings LLC. bought a new stake in Teleflex during the second quarter valued at approximately $175,000. OLD Mutual Customised Solutions Proprietary Ltd. grew its position in Teleflex by 200.0% during the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Teleflex during the second quarter valued at approximately $200,000. Calamos Advisors LLC bought a new stake in Teleflex during the second quarter valued at approximately $206,000. Finally, Harvey Capital Management Inc. bought a new stake in Teleflex during the second quarter valued at approximately $207,000. Institutional investors own 89.78% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Raymond James Financial Services Advisors Inc. Sells 128 Shares of Teleflex Incorporated (TFX)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/10/30/raymond-james-financial-services-advisors-inc-sells-128-shares-of-teleflex-incorporated-tfx.html.
Several equities analysts have weighed in on TFX shares. Leerink Swann raised shares of Teleflex from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $227.00 to $266.00 in a report on Thursday, September 7th. Zacks Investment Research downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Thursday, August 31st. Jefferies Group LLC reaffirmed a “buy” rating and set a $230.00 price target on shares of Teleflex in a report on Thursday, August 3rd. KeyCorp reaffirmed a “hold” rating on shares of Teleflex in a report on Wednesday, September 6th. Finally, BidaskClub downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $260.75.
Teleflex Incorporated (NYSE TFX) opened at 242.79 on Monday. Teleflex Incorporated has a one year low of $136.53 and a one year high of $248.68. The firm’s 50-day moving average is $240.40 and its 200 day moving average is $214.43. The stock has a market cap of $10.93 billion, a P/E ratio of 46.43 and a beta of 1.07.
Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.13. The business had revenue of $528.60 million for the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the company earned $1.89 EPS. On average, analysts anticipate that Teleflex Incorporated will post $8.29 EPS for the current fiscal year.
In other news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $211.75, for a total transaction of $42,350.00. Following the sale, the director now owns 8,080 shares of the company’s stock, valued at approximately $1,710,940. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 600 shares of company stock worth $132,408 in the last ninety days. Corporate insiders own 2.39% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
What are top analysts saying about Teleflex Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teleflex Incorporated and related companies.